3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
2
Status
Completed
2
Withdrawn
1
Recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Urogenital Neoplasms
2
Prostatic Neoplasms
2
Prostatic Diseases
2
Neoplasms by Site
2
Neoplasms
2
Male Urogenital Diseases
2
Genital Neoplasms, Male
2
Genital Diseases, Male
2
Carcinoma
2
Interventions
Cyclophosphamide
299
Cisplatin
298
Paclitaxel
257
Radiotherapy
255
Fluorouracil
234
Carboplatin
234
Docetaxel
230
Doxorubicin
216
Dexamethasone
166
Gemcitabine
156
Vincristine
147
Etoposide
136
Leucovorin
133
Capecitabine
129
Bevacizumab
129
Prednisone
125
Rituximab
118
Methotrexate
118
Cytarabine
110
Filgrastim
99
Trastuzumab
97
Oxaliplatin
96
pembrolizumab
83
Pemetrexed
73
Epirubicin
70
Tamoxifen
69
Drug Therapy
69
Irinotecan
65
Granulocyte Colony-Stimulating Factor
60
Daunorubicin
58
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Completed
×
padeliporfin
×
Clear all
NCT01310894
2019-07-11
PCM301
Steba Biotech S.A.
Phase 3
Completed
413 enrolled
NCT01875393
2016-04-19
PCM304
Steba Biotech S.A.
Phase 3
Completed
81 enrolled